Detailed Abstract
[E-poster]
[EP100] Comparing the Oncologic Outcomes of Pancreatic Ductal Adenocarcinoma and Invasive Intraductal Papillary Mucinous Neoplasms
Munseok CHOI1, 2, Chang Moo KANG*1, 2, Ho Kyoung HWANG1, 2, Woo Jung LEE1, 2
1Department of Surgery, Yonsei University College of Medicine, Korea
2Division of Hepatobiliary and Pancreatic Surgery, Yonsei University College of Medicine, Korea
Introduction : The study aimed to compare survival outcomes between patients with pancreatic ductal adenocarcinoma (PDAC) and invasive intraductal papillary mucinous neoplasms (IPMN) and identify the prognostic factor of invasive IPMN
Methods : A total of 264 consecutive patients, including 216 PDAC and 48 invasive IPMN patients, were reviewed. Stage-matched survival analysis was conducted, and to evaluate the prognostic factors, univariate and multivariate Cox regression analysis was performed.
Results : According to the AJCC-TNM staging system, the distribution of invasive IPMN vs. PDAC was stage I (31.9 vs. 35.7%), stage II (57.5 vs. 47.2%) and stage III (10.6 vs. 17.1%). Overall survival of invasive IPMN showed better long-term oncologic outcome than those of PDAC (108.5 vs 30.0 months, p<0.001). When the analysis was confined to stage II patients, overall survival (OS) and disease-free survival (DFS) for invasive IPMN was significantly longer than that for PDAC(p<0.001). However, no difference was observed in stage I and III patients. Multivariate analysis revealed that only R0 was an independent prognostic factor for OS of invasive IPMN (hazard ratio, 16.419, p=0.002). Perineural invasion and adjuvant chemotherapy were the factors influencing DFS in multivariate analysis (hazard ratio, 3.646, p=0.025, HR 6.660, p=0.007, simultaneously).
Conclusions : Only in Stage II group, invasive IPMN showed better DFS and OS than PDAC. Active postoperative chemotherapy should be considered in invasive IPMN patients, as well as the investigation of effective chemotherapeutic agents to treat resected invasive IPMN.
Methods : A total of 264 consecutive patients, including 216 PDAC and 48 invasive IPMN patients, were reviewed. Stage-matched survival analysis was conducted, and to evaluate the prognostic factors, univariate and multivariate Cox regression analysis was performed.
Results : According to the AJCC-TNM staging system, the distribution of invasive IPMN vs. PDAC was stage I (31.9 vs. 35.7%), stage II (57.5 vs. 47.2%) and stage III (10.6 vs. 17.1%). Overall survival of invasive IPMN showed better long-term oncologic outcome than those of PDAC (108.5 vs 30.0 months, p<0.001). When the analysis was confined to stage II patients, overall survival (OS) and disease-free survival (DFS) for invasive IPMN was significantly longer than that for PDAC(p<0.001). However, no difference was observed in stage I and III patients. Multivariate analysis revealed that only R0 was an independent prognostic factor for OS of invasive IPMN (hazard ratio, 16.419, p=0.002). Perineural invasion and adjuvant chemotherapy were the factors influencing DFS in multivariate analysis (hazard ratio, 3.646, p=0.025, HR 6.660, p=0.007, simultaneously).
Conclusions : Only in Stage II group, invasive IPMN showed better DFS and OS than PDAC. Active postoperative chemotherapy should be considered in invasive IPMN patients, as well as the investigation of effective chemotherapeutic agents to treat resected invasive IPMN.
SESSION
E-poster
E-Session 7/27 ~ 7/29 ALL DAY